Literature DB >> 16375680

Molecular biology of the enzymes that degrade endocannabinoids.

Robyn A Puffenbarger1.   

Abstract

Endocannabinoid circuits have been shown to regulate a number of important pathways including pain, feeding, memory and motor coordination. Direct manipulation of endocannabinoid tone, therefore, may relieve disease symptoms related to analgesia, obesity, Alzheimer's and Parkinson's in humans. The endocannabinoid circuit involves two cloned receptors: CB1 in the CNS and CB2 in the periphery; endogenously produced ligands including anandamide, 2-arachidonylglycerol and palmitoylethanolamide; and enzymes that degrade endocannabinoid ligands to terminate signaling. Currently, three enzymes have been characterized with the ability to hydrolyze endocannabinoids: fatty acid amide hydrolase (FAAH), monoglyceride lipase (MGL) and N-acylethanolamine-hydrolyzing acid amidase (NAAA). The purpose of this review is to examine the molecular biology for the enzymes that hydrolyze endocannabinoids covering the protein activity and expression, mRNA characterization, genomic locus organization, promoter analysis and knockout phenotypes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16375680     DOI: 10.2174/156800705774933050

Source DB:  PubMed          Journal:  Curr Drug Targets CNS Neurol Disord        ISSN: 1568-007X


  8 in total

1.  Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice.

Authors:  M Bashashati; M A Storr; S P Nikas; J T Wood; G Godlewski; J Liu; W Ho; C M Keenan; H Zhang; S O Alapafuja; B F Cravatt; B Lutz; K Mackie; G Kunos; K D Patel; A Makriyannis; J S Davison; K A Sharkey
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Time-dependent expression and distribution of monoacylglycerol lipase during the skin-incised wound healing in mice.

Authors:  Wen-Xiang Ma; Tian-Shui Yu; Yan-Yan Fan; Shu-Tao Zhang; Peng Ren; Shuai-Bo Wang; Rui Zhao; Jing-Bo Pi; Da-Wei Guan
Journal:  Int J Legal Med       Date:  2011-04-08       Impact factor: 2.686

Review 3.  Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.

Authors:  V Kiran Vemuri; David R Janero; Alexandros Makriyannis
Journal:  Physiol Behav       Date:  2007-11-21

4.  Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors.

Authors:  Martin A Storr; Catherine M Keenan; Dominik Emmerdinger; Hong Zhang; Birol Yüce; Andrei Sibaev; Federico Massa; Nancy E Buckley; Beat Lutz; Burkhard Göke; Stephan Brand; Kamala D Patel; Keith A Sharkey
Journal:  J Mol Med (Berl)       Date:  2008-05-21       Impact factor: 4.599

Review 5.  Cannabinoids, endocannabinoids, and related analogs in inflammation.

Authors:  Sumner H Burstein; Robert B Zurier
Journal:  AAPS J       Date:  2009-02-06       Impact factor: 4.009

Review 6.  Isoniazid metabolism and hepatotoxicity.

Authors:  Pengcheng Wang; Komal Pradhan; Xiao-Bo Zhong; Xiaochao Ma
Journal:  Acta Pharm Sin B       Date:  2016-08-03       Impact factor: 11.413

7.  Mutation screen and association studies for the fatty acid amide hydrolase (FAAH) gene and early onset and adult obesity.

Authors:  Timo D Müller; Günter Brönner; Melanie Wandolski; Jophia Carrie; Trang T Nguyen; Brandon H Greene; André Scherag; Harald Grallert; Carla Ig Vogel; Susann Scherag; Winfried Rief; Hans-Erich Wichmann; Thomas Illig; Helmut Schäfer; Johannes Hebebrand; Anke Hinney
Journal:  BMC Med Genet       Date:  2010-01-01       Impact factor: 2.103

8.  Lack of association of genetic variants in genes of the endocannabinoid system with anorexia nervosa.

Authors:  Timo Dirk Müller; Kathrin Reichwald; Günter Brönner; Jeanette Kirschner; Thuy Trang Nguyen; André Scherag; Wolfgang Herzog; Beate Herpertz-Dahlmann; Peter Lichtner; Thomas Meitinger; Matthias Platzer; Helmut Schäfer; Johannes Hebebrand; Anke Hinney
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2008-11-17       Impact factor: 3.033

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.